HCP1306
Phase 3Small molecule
Hanmi Pharmaceutical Company LimitedHCP1306 is one of 37 small molecule programs targeting Hypercholesterolemia. It is currently in Phase 3.
1
Indications
6
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
130 competitors in Hypercholesterolemia
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Lescol
NovartisPhase 3
Micardis
Boehringer IngelheimPhase 3
Comparator: Statins
Merck & Co.Phase 3
Statin
Bristol-Myers SquibbPhase 3
Evacetrapib
Eli LillyPhase 3
Kynamro
KKastle Therapeutics, LLC
Phase 3
Enlicitide
Merck & Co.Phase 3
Anacetrapib
Merck & Co.Phase 3
Lapaquistat Acetate
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tics3 trials
Interaction2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HCP1306. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details